Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III sold 53,767 shares of the company’s stock in a transaction on Monday, June 18th. The stock was sold at an average price of $39.88, for a total value of $2,144,227.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Xencor opened at $37.01 on Friday, Marketbeat.com reports. Xencor Inc has a fifty-two week low of $18.97 and a fifty-two week high of $43.39.
Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.16). Xencor had a negative net margin of 137.35% and a negative return on equity of 18.07%. sell-side analysts predict that Xencor Inc will post -2.33 EPS for the current year.
XNCR has been the topic of a number of recent analyst reports. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a report on Saturday, April 7th. Wedbush upped their price objective on Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, March 19th. Cantor Fitzgerald reissued a “buy” rating and issued a $37.00 target price on shares of Xencor in a report on Thursday, March 29th. Leerink Swann reissued an “outperform” rating and issued a $36.00 target price on shares of Xencor in a report on Wednesday, March 28th. Finally, ValuEngine raised Xencor from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $37.88.
Several institutional investors and hedge funds have recently bought and sold shares of XNCR. Redmile Group LLC boosted its stake in shares of Xencor by 137.2% during the first quarter. Redmile Group LLC now owns 3,204,343 shares of the biopharmaceutical company’s stock valued at $96,066,000 after acquiring an additional 1,853,449 shares during the last quarter. BVF Inc. IL acquired a new stake in shares of Xencor during the first quarter valued at $27,042,000. PointState Capital LP acquired a new stake in shares of Xencor during the first quarter valued at $14,300,000. Artal Group S.A. boosted its stake in shares of Xencor by 200.0% during the first quarter. Artal Group S.A. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $8,994,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in shares of Xencor during the first quarter valued at $4,494,000. 79.54% of the stock is currently owned by institutional investors and hedge funds.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.